Characterization of a drug-targetable allosteric site regulating vascular endothelial growth factor signaling
- 281 Downloads
Vascular endothelial growth factors (VEGFs) regulate blood and lymph vessel development upon activation of three receptor tyrosine kinases (VEGFRs). The extracellular domain of VEGFRs consists of seven Ig-homology domains, of which D2–3 form the ligand-binding site, while the membrane proximal domains D4–7 are involved in homotypic interactions in ligand-bound receptor dimers. Based on low-resolution structures, we identified allosteric sites in D4–5 and D7 of vascular endothelial growth factor receptor 2 (VEGFR-2) accomplishing regulatory functions. Allosteric inhibition of VEGFR-2 signaling represents an attractive option for the treatment of neovascular diseases. We showed earlier that DARPin® binders to domains D4 or D7 are potent VEGFR-2 inhibitors. Here we investigated in detail the allosteric inhibition mechanism of the domain D4 binding inhibitor D4b. The 2.38 Å crystal structure of D4b in complex with VEGFR-2 D4–5, the first high-resolution structure of this VEGFR-2 segment, indicates steric hindrance by D4b as the mechanism of inhibition of receptor activation. At the cellular level, D4b triggered quantitative internalization of VEGFR-2 in the absence of ligand and thus clearance of VEGFR-2 from the surface of endothelial cells. The allosteric VEGFR-2 inhibition was sufficiently strong to efficiently inhibit the growth of human endothelial cells at suboptimal dose in a mouse xenograft model in vivo, underlining the therapeutic potential of the approach.
KeywordsAngiogenesis VEGF DARPin VEGFR-2 KDR Inhibition Receptor downregulation
Andreas Cornelius, Johan Abram and Nicole Bassler of Molecular Partners are acknowledged for production and characterization of D4b and HD4b. We thank Drs. Richard Kammerer and Roger Benoit for designing the receptor D4–5 construct, Dr. Aurélien Rizk for advice with Squassh analysis, and Mayanka Asthana for assistance in protein purification. We also thank staff at beamline X06SA at the Swiss Light Source in Villigen Switzerland for help with X-ray data acquisition. This work was supported by grants from Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (31003A_152908 to KB-H) and Oncosuisse (KLS-3569-02-2015 to KB-H).
Experiments were conceived, designed and interpreted by HKB, SMM, CLP, DA and KB-H. Experiments were performed by KMT, CLP, DA and SMM. The manuscript was written by KMT, CLP, DA, SMM, HKB and KB-H.
Compliance with ethical standards
Conflict of interest
HKB is shareholder of Molecular Partners AG commercializing the DARPin® Technology. The other authors do not declare competing financial interests.
- 7.Veikkola T, Jussila L, Makinen T, Karpanen T, Jeltsch M, Petrova TV, Kubo H, Thurston G, McDonald DM, Achen MG, Stacker SA, Alitalo K (2001) Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J 20:1223–1231CrossRefPubMedPubMedCentralGoogle Scholar
- 10.Leppänen VM, Tvorogov D, Kisko K, Prota AE, Jeltsch M, Anisimov A, Markovic-Mueller S, Stuttfeld E, Goldie KN, Ballmer-Hofer K, Alitalo K (2013) Structural and mechanistic insights into VEGF receptor 3 ligand binding and activation. Proc Natl Acad Sci USA 110(32):12960–12965CrossRefPubMedGoogle Scholar
- 20.Inai T, Mancuso M, Hashizume H, Baffert F, Haskell A, Baluk P, Hu-Lowe DD, Shalinsky DR, Thurston G, Yancopoulos GD, McDonald DM (2004) Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 165(1):35–52CrossRefPubMedPubMedCentralGoogle Scholar
- 22.Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9(1):327–337PubMedGoogle Scholar
- 26.Waterman DG, Winter G, Parkhurst JM, Fuentes-Montero L, Hattne J, Brewster A, Sauter NK, Evans G (2013) The DIALS framework for integration software. CCP4 Newsl Protein Crystallogr 49:16–19Google Scholar
- 30.Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, Echols N, Headd JJ, Hung LW, Kapral GJ, Grosse-Kunstleve RW, McCoy AJ, Moriarty NW, Oeffner R, Read RJ, Richardson DC, Richardson JS, Terwilliger TC, Zwart PH (2010) PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr 66(Pt 2):213–221CrossRefPubMedPubMedCentralGoogle Scholar
- 47.Tiede C, Bedford R, Heseltine SJ, Smith G, Wijetunga I, Ross R, AlQallaf D, Roberts AP, Balls A, Curd A, Hughes RE, Martin H, Needham SR, Zanetti-Domingues LC, Sadigh Y, Peacock TP, Tang AA, Gibson N, Kyle H, Platt GW, Ingram N, Taylor T, Coletta LP, Manfield I, Knowles M, Bell S, Esteves F, Maqbool A, Prasad RK, Drinkhill M, Bon RS, Patel V, Goodchild SA, Martin-Fernandez M, Owens RJ, Nettleship JE, Webb ME, Harrison M, Lippiat JD, Ponnambalam S, Peckham M, Smith A, Ferrigno PK, Johnson M, McPherson MJ, Tomlinson DC (2017) Affimer proteins are versatile and renewable affinity reagents. Elife. https://doi.org/10.7554/eLife.24903 PubMedPubMedCentralCrossRefGoogle Scholar